Amgen, Inc. (NASDAQ:AMGN) was downgraded by investment analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Monday, Analyst Ratings Network.com reports. They presently have a $159.22 price target on the medical research company’s stock. Vetr‘s price target would indicate a potential upside of 8.31% from the company’s previous close.
A number of hedge funds have made changes to their positions in the stock. Norges Bank acquired a new stake in shares of Amgen during the fourth quarter valued at about $1,071,028,000. BlackRock Advisors LLC raised its stake in shares of Amgen by 40.1% in the fourth quarter. BlackRock Advisors LLC now owns 3,746,237 shares of the medical research company’s stock valued at $608,126,000 after buying an additional 1,071,485 shares during the period. Janus Capital Management raised its stake in shares of Amgen by 13.0% in the third quarter. Janus Capital Management now owns 8,462,298 shares of the medical research company’s stock valued at $1,170,520,000 after buying an additional 975,635 shares during the period. Vanguard Group Inc. raised its stake in shares of Amgen by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 44,916,785 shares of the medical research company’s stock valued at $7,291,342,000 after buying an additional 953,984 shares during the period. Finally, Voya Investment Management LLC raised its stake in shares of Amgen by 24.0% in the fourth quarter. Voya Investment Management LLC now owns 2,225,163 shares of the medical research company’s stock valued at $361,211,000 after buying an additional 430,656 shares during the period.
Source: American Banking and Market News